1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma

Wilky, B., Trent, J. C., Gordon, M., El-Khoueiry, A. B., Bullock, A., Henick, B. S., Schwartz, G. K., Agulnik, M., Mahadevan, D., Patel, J., Grossman, J., Rosenthal, K., O’Day, S. J., & Tsimberidou, A. M. (2023). 1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma. Annals of Oncology, 34, S1032–S1033. https://doi.org/10.1016/j.annonc.2023.09.1148
Authors:
Breelyn A. Wilky
Jonathan C. Trent
Michael S. Gordon
Anthony B. El-Khoueiry
Andrea J. Bullock
Brian S. Henick
Gary K. Schwartz
Mark Agulnik
Daruka Mahadevan
Jyoti D. Patel
Joseph E. Grossman
Katherine Rosenthal
Steven O’Day
Apostolia M. Tsimberidou
Affiliated Authors:
Brian S. Henick
Gary K. Schwartz
Columbia Affiliation:
Subjects:
Sarcoma Research and Treatment (OpenAlex Topic)
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
Cancer Immunotherapy (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1016/j.annonc.2023.09.1148
DOI:
10.1016/j.annonc.2023.09.1148
Journal:
Annals of Oncology
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: